GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Supriya Lifescience Ltd (BOM:543434) » Definitions » Change In Receivables

Supriya Lifescience (BOM:543434) Change In Receivables : ₹0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Supriya Lifescience Change In Receivables?

Supriya Lifescience's change in receivables for the quarter that ended in Dec. 2024 was ₹0 Mil. It means Supriya Lifescience's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Supriya Lifescience's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-272 Mil. It means Supriya Lifescience's Accounts Receivable increased by ₹272 Mil from Mar. 2023 to Mar. 2024 .

Supriya Lifescience's Accounts Receivable for the quarter that ended in Dec. 2024 was ₹0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Supriya Lifescience's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Supriya Lifescience's liquidation value for the three months ended in Dec. 2024 was ₹0 Mil.


Supriya Lifescience Change In Receivables Historical Data

The historical data trend for Supriya Lifescience's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supriya Lifescience Change In Receivables Chart

Supriya Lifescience Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Change In Receivables
Get a 7-Day Free Trial 173.52 -250.31 -447.36 305.45 -271.55

Supriya Lifescience Quarterly Data
Mar19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Supriya Lifescience Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Supriya Lifescience  (BOM:543434) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Supriya Lifescience's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/1856.48*91
=0.00

2. In Ben Graham's calculation of liquidation value, Supriya Lifescience's accounts receivable are only considered to be worth 75% of book value:

Supriya Lifescience's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0-0+0.75 * 0+0.5 * 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Supriya Lifescience Change In Receivables Related Terms

Thank you for viewing the detailed overview of Supriya Lifescience's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Supriya Lifescience Business Description

Traded in Other Exchanges
Address
Sonawala Road, 207/208, Udyog Bhavan, Goregaon East, Mumbai, MH, IND, 400063
Supriya Lifescience Ltd is a manufacturer of Active pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

Supriya Lifescience Headlines

No Headlines